Search

Author/Creator Stutvoet, Simone

1. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). Issue 1 (21st May 2019)

Authors:
Maher, Toby M; Kreuter, Michael; Lederer, David J; Brown, Kevin K; Wuyts, Wim; Verbruggen, Nadia; Stutvoet, Simone; Fieuw, Ann; Ford, Paul; Abi-Saab, Walid; Wijsenbeek, Marlies
Journal:
BMJ open respiratory research
Issue:
Volume 6:Issue 1(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials. (23rd April 2019)

Authors:
van der Aar, Ellen; Desrivot, Julie; Dupont, Sonia; Heckmann, Bertrand; Fieuw, Ann; Stutvoet, Simone; Fagard, Liesbeth; Van de Wal, Karen; Helmer, Eric
Journal:
Journal of clinical pharmacology
Issue:
Volume 59:Number 10(2019)
Page Start:
1366
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗